Document Detail


Dose finding studies with imidapril--a new ACE inhibitor.
MedLine Citation:
PMID:  8198936     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. We describe an approach involving a smaller, shorter study, leading onto a longer, larger study in which the antihypertensive effects of ascending doses of imidapril, a new ACE inhibitor, were investigated. Both studies were planned prospectively, assuming a clinically useful fall in BP to be 8 mm Hg (s.d. = 9). The studies included patients with mild to moderate essential hypertension (baseline sitting diastolic blood pressure (SDBP) 95-115 mm Hg). After a placebo run-in of 2-3 weeks patients received either placebo or imidapril 2.5, 5, 10 or 20 mg in the 2 week study (n = 91) or imidapril 5, 10, 20 or 40 mg in the 4 week study (n = 162). 2. The overall mean baseline SDBP was 103.4 mm Hg (s.d. 0.62) in the initial study and 101.5 mm Hg (s.d. 0.41) in the 4 week study. 3. Compared with placebo, imidapril 10, 20 and 40 mg significantly reduced SDBP. There was no significant difference between these doses, suggesting that 10 mg achieved maximal ACE inhibition in most patients. The 2.5 mg dose showed no significant effect. The 5 mg dose gave an intermediate effect. In both studies the overall incidence of adverse events was similar in the imidapril and placebo groups, and was not worrying.
Authors:
M J Vandenburg; E M Mackay; I Dews; T Pullan; S Brugier
Related Documents :
3533566 - Relationship between the venoconstrictor activity of dihydroergotamine and its pharmaco...
551896 - The effects of long term oral treatment with indapamide on the development of doca-salt...
20017916 - Thermogenic effect of meltdown rtd energy drink in young healthy women: a double blind,...
24582046 - Comparison of different strategies of ivabradine premedication for heart rate reduction...
16162976 - A phase i and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix ...
2174626 - Central and peripheral alpha-adrenergic control of ileal, caecal and proximal colonic m...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  37     ISSN:  0306-5251     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  1994 Mar 
Date Detail:
Created Date:  1994-07-07     Completed Date:  1994-07-07     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  265-72     Citation Subset:  IM    
Affiliation:
MCRC, Romford, Essex, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*,  adverse effects,  pharmacology,  therapeutic use
Blood Pressure / drug effects*
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Hypertension / drug therapy*
Imidazoles / administration & dosage*,  adverse effects,  pharmacology,  therapeutic use
Imidazolidines*
Male
Middle Aged
Prospective Studies
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Imidazoles; 0/Imidazolidines; 89396-94-1/imidapril
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The acute effects of a single dopamine infusion in elderly patients with congestive cardiac failure.
Next Document:  Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and dia...